ProQR raises $90.6M in upsized offering

ProQR Therapeutics N.V. (NASDAQ:PRQR) raised $104.1 million on Sept. 11 through the sale of 6.6 million shares at $15.75 in a bumped-up follow-on underwritten by Citigroup, Evercore ISI, RBC Capital Markets, H.C. Wainwright and Chardan.

On Sept. 5, ProQR said new data showed that its RNA-based therapeutic QR-110 led to rapid and sustained visual improvements in a Phase I/II trial to treat Leber congenital amaurosis type 10 (LCA10). The company plans to start a pivotal Phase I/II trial next half in LCA10 patients with the p.Cys998X mutation in the centrosomal protein 290kDa (CEP290) gene, which QR-110 is designed to repair (see "ProQR Planning Pivotal Trial of Vision Loss Candidate")...